Success Story: I-140 NIW Approved For A Cancer Immunotherapy Researcher Without RFE
Client’s Testimonial:
“I am very satisfied with the overall case preparation process. The team has been extremely professional, and all my questions were addressed with timely and clear responses. I truly appreciate your support throughout the process.”
On March 2nd, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the Field of Cancer Immunotherapy (Approval Notice).
General Field: Cancer Immunotherapy
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: China
State of Residence at the Time of Filing: Missouri
Approval Notice Date: March 2nd, 2026
Processing Time: 5 months, 11 days (Premium Processing Upgrade Requested)
Case Summary:
Cancer immunotherapy often comes down to a difficult balance, activating potent anti-tumor immunity while keeping treatment safe and precisely targeted. Drawing on our extensive experience and a proven track record of more than 32,000 approved cases, our team recently secured an I-140 National Interest Waiver approval for the client, a researcher focused on next-generation T cell-based immunotherapy.
Background & Field of Expertise
The client holds a D.Sc. in microbial and biochemical pharmacy and has developed deep expertise in cancer immunotherapy. The proposed endeavor is to continue designing, developing, and translating innovative T cell-based immunotherapeutic strategies to enhance anti-tumor immunity and improve cancer outcomes.
The client is currently conducting research at a U.S. research university, providing a clear platform to continue advancing this work through ongoing investigations and publication.
Strong Evidence of Research Excellence
To show the client is well-positioned to advance an endeavor of clear, substantial merit and national importance, we presented an objective record of peer-validated output and influence, including:
- 22 peer-reviewed journal articles, including multiple first-authored or co-first-authored publications
- 1 granted patent
- 1,120 citations to the client’s published work
We did not treat these numbers as self-explanatory. Instead, we framed them the way an adjudicator weighs NIW evidence. A citation record at this level reflects sustained independent reliance, meaning other researchers have repeatedly used the client’s findings as a foundation for their own work. The patent provided an additional credibility anchor because it signals practical translation beyond publication alone. Together, these indicators supported a straightforward conclusion: the client’s contributions have already shaped how others in the field approach key questions in immunotherapy, and the proposed endeavor has a credible pathway to broader public benefit in oncology.
The Approval
The I-140 NIW petition was approved, reflecting the strength of a clearly defined endeavor paired with evidence of sustained peer-validated impact. This outcome highlights that when cancer immunotherapy research is presented with a concrete public benefit pathway and supported by objective signs of independent reliance, it can meet the NIW standard while remaining focused, credible, and privacy protective.